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CLINICAL RESEARCH
Atrial fibrillation
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Methods
and results
We ascertained AF incidence in 18 556 Whites and African Americans from the Atherosclerosis Risk in Communities
Study (ARIC, n¼10 675), Cardiovascular Health Study (CHS, n ¼ 5043), and Framingham Heart Study (FHS, n ¼ 2838),
followed for 5 years (prediction horizon). We added BNP (ARIC/CHS: N-terminal pro-B-type natriuretic peptide; FHS:
BNP), CRP, or both to a previously reported AF risk score, and assessed model calibration and predictive ability [C-
statistic, integrated discrimination improvement (IDI), and net reclassification improvement (NRI)]. We replicated
models in two independent European cohorts: Age, Gene/Environment Susceptibility Reykjavik Study (AGES),
n ¼ 4467; Rotterdam Study (RS), n ¼ 3203. B-type natriuretic peptide and CRP were significantly associated with AF
incidence (n ¼ 1186): hazard ratio per 1-SD ln-transformed biomarker 1.66 [95% confidence interval (CI), 1.56–
1.76], P, 0.0001 and 1.18 (95% CI, 1.11–1.25), P, 0.0001, respectively. Model calibration was sufficient (BNP,
x2 ¼ 17.0; CRP, x2 ¼ 10.5; BNP and CRP, x2 ¼ 13.1). B-type natriuretic peptide improved the C-statistic from 0.765
to 0.790, yielded an IDI of 0.027 (95% CI, 0.022–0.032), a relative IDI of 41.5%, and a continuous NRI of 0.389 (95%
CI, 0.322–0.455). The predictive ability of CRP was limited (C-statistic increment 0.003). B-type natriuretic peptide
consistently improved prediction in AGES and RS.
Conclusion B-type natriuretic peptide, not CRP, substantially improved AF risk prediction beyond clinical factors in an independently
replicated, heterogeneous population. B-type natriuretic peptide may serve as a benchmark to evaluate novel putative
AF risk biomarkers.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Atrial fibrillation † Risk prediction † Epidemiology † Biomarker † B-type natriuretic peptide † C-reactive
protein
Introduction
Prediction of atrial fibrillation (AF), a common cardiac arrhythmia,
has been the focus of various recent publications. Based on factors
easily obtained during a standard office visit, a first AF risk score
was developed by investigators from the Framingham Heart Study
(FHS).1 The score was subsequently validated in the Age Gene/Envir-
onment Susceptibility-Reykjavik (AGES) Study and the Cardiovascular
Health Study (CHS),2 and different, yet comparable scores were
established in the Atherosclerosis Risk in Communities (ARIC)
Study3 and the Malmo¨ Cancer and Diet Study.4 Most recently, the
Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) AF consortium proposed a new risk model, combining
individuals of heterogeneous racial and geographical backgrounds.
This model predicted AF reasonably well in both derivation and
validation cohorts.5
The CHARGE-AF risk score comprises only clinical risk factors
for AF.5 Factors included are age, race, height, weight, systolic and
diastolic blood pressure, smoking status, use of antihypertensive
medication, presence of diabetes mellitus, a history of heart failure,
and a history of myocardial infarction.
Abundant literature describes the relation between laboratory
biomarkers and AF. B-type and N-terminal pro B-type natriuretic
peptides (BNP)4,6– 12 and C-reactive protein (CRP),10,13–16 two bio-
markers routinely determined in clinical practice, have repeatedly
been shown to be associated with AF. However, their role in AF
risk reclassification has not been studied in large racially and geo-
graphically diverse populations.
We investigated whether the addition of BNP and CRP mea-
surements to the CHARGE-AF risk score improved the prediction
of AF in racially and geographically diverse cohorts. We hypo-
thesized that information on these biomarkers improves AF risk
reclassification.
Methods
Study sample
We combined individual-level data from three US community-based
studies (ARIC, CHS, and FHS) to estimate the predictive performance
of the previously derived CHARGE-AF risk score5 after addition of the
biomarker information. Subsequently, we replicated our results in two
community-based studies of individuals of European descent [AGES,
Rotterdam Study (RS)]. We excluded participants with prevalent AF at
baseline, age ≤45 or ≥95 years, with impaired renal function affecting
biomarker clearance (defined as serum creatinine levels ≥2.0 mg/dl),
not of European or African ancestry, and missing covariates, BNP, or
CRP (described in Supplementary material online, Table S1). Detailed
descriptions of cohorts, AF ascertainment methods, and assessment of
clinical variables are found in the Supplementary material online.
Written informed consent was obtained from all participants, Institution-
al Review Boards at each participating institution approved each cohort
study, and all procedures complied with the principles outlined in the
Declaration of Helsinki.
Assessment of biomarkers
Details on BNP and CRP assays used in each study are provided in the
Supplementary material online, Table S2. All biomarkers were deter-
mined from blood samples drawn at the index visit (see Supplementary
material online, Supplemental methods). Framingham Heart Study mea-
sured BNP, whereas all other cohorts measured N-terminal proBNP.
N-terminal proBNP is more reproducible at the lower end of the distri-
bution range, and more stable at room temperature.17 However, both
BNP and N-terminal proBNP are clinically available and have been
shown to be strongly correlated: r ¼ 0.89,18 and r . 0.87.19
Statistical methods
We expressed continuous variables as mean+ standard deviation (SD)
and categorical variables as frequency and percentage. Individual-level
BNP and CRP in the prediction of AF risk 1427
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data from ARIC, CHS, and FHS were pooled into a single derivation
cohort. Values for N-terminal proBNP were divided by 10 to achieve
values of similar numerical magnitude as the BNP values. Prior research
had shown that values of N-terminal proBNP are10 times larger com-
pared with values of BNP obtained from the same patient.20 Biomarkers
were then natural logarithm-transformed (ln-transformed) to avoid
undue influence of large values. Finally, biomarker measurements in
our study were standardized by cohort, sex, and race (if applicable),
allowing us to combine BNP and N-terminal proBNP in our models.
Values below the assays’ detection limits were set to the respective
detection limits.
The initial CHARGE-AF risk score calculated a proportional hazard
prediction model adjusted for age, race, height, weight, systolic and dia-
stolic blood pressure, antihypertensive treatment, smoking status, dia-
betes, heart failure, and myocardial infarction. Variables were selected
from a larger pool using backward selection.5 For all models, we tested
the proportionality of hazards assumption using time-dependent covari-
ates. For inclusion of BNP, CRP, or BNP and CRP, performance was
assessed for a 5-year prediction horizon; the maximum follow-up until
censoring was 7 years. We tested for interactions of each biomarker
with age, sex, race, and body mass index. Effect estimates for biomarkers
are reported as hazard ratios (HRs) per 1-SD increase of ln-transformed
values. Hazard ratios for other covariates are presented per clinically
meaningful unit. We plotted curves for the cumulative incidence of AF
by biomarker quartile, not adjusting for the competing risk of death.
We also investigated the relation between AF risk and continuous
biomarker levels using spline regression.21
We assessed the model’s performance to predict the 5-year risk of AF
by calculating the C-statistic. Model calibration was determined by the
Hosmer–Lemeshow x2 statistic, modified for survival analysis.22 The
added predictive ability of the biomarkers was assessed by the difference
in C-statistics of models before and after biomarker inclusion. We add-
itionally investigated the integrated discrimination improvement (IDI)
and relative IDI.23 Reclassification of participants was assessed by cat-
egorical net reclassification improvement (NRI) into risk categories of
the cumulative proportion developing AF over 5 years. The categories
were defined as ,2.5, 2.5–5.0, and .5.0% based on experience from
prior studies.5,24 We also calculated the continuous NRI.23,25
The models including biomarker information were subsequently repli-
cated in AGES and RS. All analyses, including the assessment of model
calibration and predictive performance, were performed as described
for the derivation cohort, applying the CHARGE-US models to the
European replication cohorts. Calibration, discrimination, and reclassifi-
cation were compared between the discovery cohort and the replication
cohorts.
To minimize confounding sources of BNP and CRP elevation, we also
performed a sensitivity analysis excluding all participants with a history of
heart failure or myocardial infarction at baseline, repeating all analyses.
All analyses were performed using SAS 9.2. P-values,0.05 were con-
sidered significant. A risk calculator with instructions is in the Supplemen-
tary material online.
Results
Overall, 18 556 participants in the derivation cohorts had full data
available, and were included in the analysis. Demographic and
biomarker characteristics can be found in Table 1 and Tables S3 and
S4 (see Supplementary material online). The mean age in the
CHARGE-US cohorts was 65 years; African American participants
were included from ARIC and CHS, and made up 17% of the deriv-
ation sample. The proportion of women was 56% in Whites and
65% in African Americans. During follow-up, 1186 individuals devel-
oped AF (419 in ARIC, 624 in CHS, 143 in FHS). Generally, women
had higher mean BNP and CRP than men. Regardless of sex,
African American participants had lower mean BNP than Whites,
but higher mean CRP.
Association of B-type natriuretic peptide
and C-reactive protein with atrial
fibrillation risk
In our derivation cohort, the levels of BNPand CRP were significantly
associated with the risk of AF, when added to the established predic-
tors derived from the CHARGE-AF risk score (Table 2, see Supple-
mentary material online, Table S5).5 A 1-SD difference of lnBNP
was associated with a HR for AF of 1.66 [95% confidence interval
(CI), 1.56–1.76; P, 0.0001]; the HR of lnCRP for AF was 1.18
(95% CI, 1.11–1.25; P, 0.0001). Similar HRs were found when
both BNP and CRP were added simultaneously to the model.
Apart from age (per 5-year increase), BNP (per 1-SD increase) had
the highest x2 values suggesting the greatest association with AF
risk. Cumulative incidence curves for AF by quartiles of BNP and
CRP are presented in Figure 1. Spline regressions confirmed a lack
of non-linear relation between ln-biomarker concentrations and ln
HR (see Supplementary material online, Figures S1 and S2). Effect esti-
mates for all other included variables have been reported previously
investigating the same individuals. These detailed results can be found
in a publicly available open access publication using the following
URL: http://jaha.ahajournals.org/content/2/2/e000102.full.5
Improvement of atrial fibrillation risk
prediction with B-type natriuretic peptide
and C-reactive protein
In the CHARGE-US derivation cohorts, the risk prediction model
without biomarkers achieved a C-statistic of 0.765 (95% CI, 0.748–
0.781).5 The increase in C-statistic is a measure to assess the magni-
tude of improvement of an added factor. Adding BNP increased the
C-statistic notably by 0.025 (95% CI, 0.015–0.034). By contrast,
adding CRP marginally increased the C-statistic: 0.003 (95% CI,
,0.000–0.006). The model including both biomarkers reached a
C-statistic similar to the one of BNP alone (Table 3). Calibration
was sufficient in all models. Hosmer–Lemeshow x2 values were
17.0 (P ¼ 0.05) for the model with BNP added, 10.5 (P ¼ 0.31) for
the model with CRP added, and 13.1 (P ¼ 0.16) for the model with
both biomarkers. A calculator for AF risk is available (see Supplemen-
tary material online).
Similar to the increase in C-statistic, the IDI quantifies the increase
in the difference between mean predicted risks for participants who
do and do not experience AF events, after adding new predic-
tor(s).23,25 Addition of BNP yielded an IDI of 0.027 (95% CI,
0.022–0.032), which demonstrated the biggest improvement in pre-
diction apart from a 5-year increase in age. The relative IDI compares
the predictive values of variables added to the model. In a model with
11 variables, the average contribution of each is 9%. Adding biomarker
information, the relative IDI of BNP was 41.5%, much greater than the
expected average increase beyond variables already included in the
model.26 The IDI of CRP was small (Table 3).
M.F. Sinner et al.1428
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A third measure of prediction improvement is the NRI. The cat-
egorical NRI reclassifies individuals into higher or lower categories
of pre-specified risk.23,25 The results with user-defined NRI categor-
ies (,2.5, 2.5–5.0, and.5.0% per 5 years) are presented in Table 4.
Overall, the user-defined NRI for BNP was 0.065 (95% CI, 0.029–
0.102). Among participants who developed AF, addition of BNP re-
classified 11% of participants into correct, higher risk categories,
but also reclassified 11% of participants into incorrect, lower risk cat-
egories. Conversely, among those who did not develop AF, inclusion
of BNP correctly reclassified 15% of individuals into lower risk
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of the cohorts
Variable CHARGE-USa AGES RS
N 18 556 4467 3203
Incident AF events 1186 (6%) 408 (9%) 177 (6%)
Clinical variables
Age, years 65 (8) 76 (6) 72 (7)
Sex, % women 57% (10 614) 60% (2697) 59% (1887)
Race, % African American 17% (3099) – –
Current smoker, % 13% (2487) 12% (546) 16% (499)
Height, cm
Women 161 (6) 161 (6) 161 (6)
Men 175 (7) 175 (6) 174 (7)
Weight, kg
Women 73 (17) 70 (13) 70 (11)
Men 85 (15) 83 (13) 80 (11)
Body mass index, kg/m2 28.1 (5.3) 27.1 (4.4) 26.9 (3.9)
Systolic blood pressure, mmHg 130 (20) 143 (21) 143 (21)
Diastolic blood pressure, mmHg 72 (11) 74 (10) 75 (11)
Hypertension treatment, % 42% (7719) 61% (2735) 37% (1189)
Diabetes, % 15% (2839) 12% (512) 10% (327)
Heart failure history, % 4% (705) 2% (77) 4% (112)
Myocardial infarction history, % 6% (1113) 7% (313) 11% (346)
Biomarkers
BNP
Median (IQR), pmol/ml 7.9 (11.90) 16.71 (21.65) 11.04 (13.41)
Ln, mean (SD) 2.08 (1.11) 2.86 (0.94) 2.48 (0.94)
CRP
Median (IQR), mg/dl 2.21 (3.87) 1.80 (2.80) 2.34 (3.24)
Ln, mean (SD) 0.82 (1.10) 0.67 (1.06) 0.83 (1.03)
aCHARGE-US data comprised 10 675 participants fromARIC, 5043 from CHS, 2838 from FHS. African Americans from ARIC and CHS only. N-terminal proBNP values were divided
by 10 for easier comparison with BNP. Data are percentage of the sample, or mean (SD) for continuous variables unless otherwise stated. IQR, Inter-quartile range; ln, natural
ln-transformed.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Hazard ratios per 1-SD difference in BNP, CRP, and BNP plus CRP
Variable CHARGE-US AGES RS
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
BNP 1.66 (1.56, 1.76) ,0.0001 2.05 (1.85, 2.27) ,0.0001 1.67 (1.43, 1.96) ,0.0001
CRP 1.18 (1.11, 1.25) ,0.0001 1.21 (1.09, 1.34) 0.0002 1.09 (0.93, 1.27) 0.30
Model with both
BNP 1.64 (1.54, 1.74) ,0.0001 2.02 (1.82, 2.24) ,0.0001 1.67 (1.42, 1.95) ,0.0001
CRP 1.12 (1.06, 1.19) 0.0001 1.12 (1.01, 1.23) 0.03 1.03 (0.88, 1.20) 0.73
Estimates for1-SD increaseof the respectivenatural ln-transformed biomarker. All estimates for BNPand CRP areadjusted for all predictors of AFestablished in the CHARGE-AF risk
score: age, race, smoking status, body mass index, height, weight, systolic and diastolic blood pressure, antihypertensive treatment, diabetes, histories of heart failure and myocardial
infarction.5 CI, confidence interval; HR, hazard ratio.
BNP and CRP in the prediction of AF risk 1429
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categories, and incorrectly reclassified 9% into higher risk categories.
The continuous NRI does not require pre-specified categories and
quantifies any change of predicted risk in the correct direction. For
BNP, we estimated a moderate continuous NRI of 0.389 (95% CI,
0.322–0.455); the continuous NRI for CRP was weak (Table 3).
Replication in two European cohorts
We replicated the new risk score with biomarkers in 4467 individuals
from AGES and 3203 from RS (Table 1). In AGES, the HR per 1-SD
increase of the ln-transformed biomarker was 2.05 (95% CI,
1.85–2.27; P, 0.0001) for BNP, and 1.21 (95% CI, 1.09–1.34;
P ¼ 0.0002) for CRP. Comparably, the HRs in RS were 1.67 (95%
CI, 1.43–1.96; P, 0.0001) for BNP, and 1.09 (95% CI, 0.93–1.27;
P ¼ 0.30) for CRP. Simultaneous inclusion of both biomarkers
yielded similar results (Table 2).
Models with added biomarkers showed good calibration in AGES
[Hosmer–Lemeshow x2: BNP: 5.8 (P ¼ 0.76); CRP: 8.2 (P ¼ 0.52);
BNP + CRP: 8.5 (P ¼ 0.48)], and borderline acceptable calibration
in RS [BNP: 16.1 (P ¼ 0.06); CRP: 15.4 (P ¼ 0.08); BNP + CRP:
25.6 (P, 0.01)]. In both replication cohorts, BNP strongly predicted
AF. Compared with the CHARGE-AF risk score, its inclusion
increased the C-statistic from 0.664 by 0.058 (95% CI, 0.040–
0.075) to 0.722 in AGES, and from 0.705 by 0.041 (95% CI, 0.019–
0.062) to 0.746 in RS. The IDI, relative IDI, and continuous NRI
results for added BNP, CRP, or both, in AGES and RS, respectively,
are presented in Table 3.
In a sensitivity analysis, we excluded participants in the derivation
and replication cohorts with prevalent heart failure or history of
myocardial infarction at baseline. CHARGE-US then comprised
16 946 individuals, AGES studied 4108, and RS 3203 participants.
Effect estimates and predictive performance for BNP and CRP
remained virtually unchanged (see Supplementary material online,
Tables S6 and S7).
Discussion
Investigating over 26 000 individuals from five distinct community-
based cohort studies from the USA and Western Europe, we
report that higher mean BNP was highly associated with AF, and,
together with age, was one of the strongest predictors of AF.
Despite the heterogeneity of our cohorts, including individuals of dif-
ferent ethnic backgrounds, countries, and healthcare settings, BNP
significantly improved discrimination and reclassification of AF risk
in both the derivation and replication cohorts. C-reactive protein
also was associated with incident AF, but its contribution to AF risk
prediction remained limited.
B-type natriuretic peptide4,6 –10,12 and CRP10,13– 16 previously
have been reported to be associated with and predict AF risk. For
both biomarkers, population-based studies have reported HRs well
in keeping with our findings. Examples for BNP are studies by Smith
et al.,4 Patton et al.,9 and Schnabel et al.10 who detected adjusted
HRs of 1.45 in a Swedish cohort, 1.66 in CHS, and 1.62 in FHS, respect-
ively (1.66 in the current study). Similarly, for CRP, Smith et al.4
reported a HR of 1.17, Conen et al.27 of 1.11, Aviles et al.28 of 1.24,
and Schnabel et al.10 of 1.25, whereas we detected a HR of 1.18.
Such consistency across studies support the interpretation that the
associations of BNP and CRP with AF are reasonably stable, despite
some overlap in participants between our current analysis and the
studies by Patton et al.,9 Aviles et al.,28 and Schnabel et al.10
The potential pathophysiological contexts relating BNP and CRP
to AF have been discussed elsewhere.10 BNP is expressed in both
atria and ventricles, and is a marker of cardiac stress and stretch pre-
dominantly in the ventricles, but partly in the atria.29 Atrial stretch
and subsequent atrial remodelling promote the occurrence of
AF.30 Importantly, in study participants freeof AFatbaseline, elevated
levels of BNP, even in the absence of overt heart disease, might
constitute an indicator of subclinical pathology, which will eventually
predispose to AF. This interpretation is also supported by the com-
parison between the cohorts in our study. Participants of AGES and
RS were markedly older than participants of CHARGE-US. Subclin-
ical cardiovascular conditions become more prevalent in the elderly.
Presumably reflecting this higher prevalence of subclinical disease in
AGES and RS, the predictive performance of BNP was better in these
two cohorts comparedwith CHARGE-US (e.g. confer to a C-statistic
of 0.025 in CHARGE-US vs. 0.058 in AGES and 0.041 in RS, respect-
ively). C-reactive protein is a marker of inflammation and oxidative
stress and as such, it might be involved in atrial remodelling and fibro-
sis, a hallmark of AF pathology.28,31 As opposed to BNP, which is
largely a cardiac-specific marker, CRP is up-regulated in a multitude
of inflammatory processes throughout the body. Its lack of predictive
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Figure 1 Cumulative incidence of AF, by biomarker quartiles.
The cumulative incidence of AF in the pooled CHARGE-US
cohorts over 5 years of follow-up, not adjusting for the competing
risk of death, is plotted for quartiles of BNP (upper panel) and CRP
(lower panel). AF, atrial fibrillation; BNP, B-type natriuretic peptide;
CRP, C-reactive protein; Q1–Q4, Quartiles 1–4.
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performance in our study might thus be a sign of lacking organ speci-
ficity. Whereas we cannot rule out subclinical pathology,our sensitiv-
ity analyses suggested that pre-existing heart failure or myocardial
infarction, two conditions known to elevate both BNP and CRP,
werenot confounding our results. Information on echocardiographic
measurements might further improve our risk prediction models.
However, with respect to a broad applicability of our risk model,
imaging techniques are more time-consuming and more expensive
than laboratory measures.
Like the previously reported version of our risk score involving
clinical covariates only,5 we aimed for our extended biomarker
version to potentially be clinically applicable. First, our study is
founded on a broad base thanks to the inclusion of over 26 000 indi-
viduals and close to 1800 AF events. Being derived from a racially and
geographically heterogeneous sample makes our model potentially
applicable to large parts of the North American and European popu-
lation. Unlike prior efforts with 10- or 14-year follow-up,4,10 our
score was designed to predict AF over a 5-year time period. Such a
time horizon may be more relevant to clinical trials and more mean-
ingful regarding clinical outcomes for patients. The widest clinical
applicability of a risk score is gained by simplicity and the use of
readily available covariates. Both BNP and CRP are laboratory
markers that have widespread medical use. The increasing availability
of point-of-care testing will make both tests also available in more
remotely located primary care settings.32
Beyond its applicability in principle, we envision several more spe-
cific possible applications of our score. Novel AF-related biomarkers
are emerging rapidly and an incomplete list includes apelin, urotensin
II, soluble CD40 ligand, osteoprotegerin, troponin, endothelin, plas-
minogen activator inhibitor-1, and YKL-40 (see Supplementary
material online, References). Given the strong predictive perform-
ance of BNP in particular, our revised score also might be considered
a standard for testing the clinical applicability and usefulness of novel
markers in the future.
A more speculative field of clinical applicability of our new score
lies in the potential future individualized diagnosis and therapy of
patients. With healthcare systems under increasing financial pres-
sure, it would be advantageous to identify individuals at high risk
for AF before the arrhythmia actually occurs. Individuals with an
elevated probability for AF might be followed more closely for
the occurrence of AF. An earlier diagnosis could then lead to imme-
diate guideline-recommended treatment for the prevention of
thrombo-embolic events, which are both hazardous for the individ-
ual and constitute a high socioeconomic burden.33 – 35 Similarly,
current trials including the EAST trial (confer www.clinicaltrials.
gov; NCT01288352) are investigating the importance of early
rhythm control treatment strategies for AF. In case of beneficial
early treatment, our risk score could support the timely identifica-
tion of potential patients for such treatment. In lack of specific
primary prevention strategies for AF, individuals at high risk might
also receive intensified treatment of risk factors to prevent the
occurrence of AF and its consequences. Initial results of clinical
investigations exemplarily suggest that weight loss and rigorous
risk factor management can reduce the burden of AF and its
related symptoms.36 For an easy access to risk estimates for AF,
our risk calculator (see Supplementary material online) might also
be embedded in electronic health records or electronic case
report forms of clinical studies. Whereas the concept of individua-
lized patient care is appealing, its practicability needs to be demon-
strated in randomized clinical trials.
Strengths and limitations
Major strengths of our study include the large sample size, the racially
and geographically diverse nature of the cohort, the analysis based on
individual-level data, and independent replication. Our study also has
limitations. First, individuals of non-European or non-African descent
were not included, reducing generalizability to other races and ethni-
cities. Secondly, our score, derived from community-based studies,
may not be relevant to inpatient settings. Thirdly, in our definition
of AF, we did not differentiate between different disease patterns
like paroxysmal, persistent, or permanent AF, or between AF and
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Predictive ability of biomarkers added to the CHARGE-AF risk score
DC-statistic (95% CI) IDI (95% CI) Relative IDI (95% CI) Continuous NRI (95% CI)
CHARGE-US
+ BNP 0.025 (0.015, 0.034) 0.027 (0.022, 0.032) 0.415 (0.342, 0.490) 0.389 (0.322, 0.455)
+ CRP 0.003 (0.000, 0.006) 0.003 (0.002, 0.005) 0.050 (0.029, 0.072) 0.154 (0.081, 0.228)
+ BNP and CRP 0.026 (0.017, 0.035) 0.030 (0.024, 0.035) 0.449 (0.369, 0.530) 0.375 (0.303, 0.448)
AGES
+ BNP 0.058 (0.040, 0.075) 0.023 (0.019, 0.028) 0.793 (0.656, 0.944) 0.612 (0.497, 0.734)
+ CRP 0.005 (20.002, 0.013) 0.001 (0.001, 0.002) 0.050 (0.021, 0.079) 0.142 (0.018, 0.269)
+ BNP and CRP 0.059 (0.041, 0.077) 0.024 (0.019, 0.029) 0.827 (0.683, 0.988) 0.633 (0.517, 0.751)
RS
+ BNP 0.041 (0.019, 0.062) 0.028 (0.020, 0.038) 0.700 (0.525, 0.883) 0.449 (0.248, 0.623)
+ CRP 20.005 (20.014, 0.004) 0.001 (0.000, 0.003) 0.032 (20.001, 0.065) 0.011 (20.178, 0.184)
+ BNP and CRP 0.039 (0.018, 0.060) 0.029 (0.020, 0.039) 0.716 (0.547, 0.900) 0.470 (0.270, 0.655)
Biomarkers are standardized within cohorts in CHARGE-US and presented per 1 SD of the natural ln-transformed biomarker. The CHARGE-AF risk score uses age, race, smoking
status, body mass index, height, systolic and diastolic blood pressure, antihypertensive treatment, diabetes, and histories of heart failure and myocardial infarction.5D, delta; CI, 95%
confidence interval; IDI, integrated discrimination improvement; NRI, net reclassification improvement.
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atrial flutter, leaving unresolved whether the utility of our prediction
model varies by specific AF pattern. Fourthly, all covariates includ-
ing biomarkers were assessed only at baseline. We thus cannot
comment on whether temporal changes of covariates or biomarkers
alter risk for AF. In particular, it remains unclear if therapies reducing
BNP and CRP levels are accompanied by reduced risk of AF. Finally,
we have only included BNP and CRP as potentially predictive bio-
markers, whereas other markers have been suggested and warrant
investigation.
Balancing advantages and disadvantages of population-based
studies and clinical trials, the former do not allow for specific
disease-related measurements, particularly if such measurements
are invasive like electrophysiological studies. Also, the ascertainment
of medical data and events often has to rely on the review of medical
charts rather than direct patient interrogation. At the same time,
however, population-based cohorts warrant high numbers of
investigated participants, which gives enough statistical power to
detect even small effects that might be overlooked in small clinical
trials. Also, the generalizability to the general public might be larger
compared with patients recruited because of a specific disease or
condition.
Conclusion
In conclusion, addition of information on BNP, and to a much smaller
extent on CRP, significantly improved the 5-year risk prediction for
AF. In particular, BNP was the strongest predictor of AF, apart
from a 5-year increase in age. The wide availability of laboratory
tests for BNP and CRP, at least in the industrialized world, might fa-
cilitate the applicability of our new risk score to a larger clinical popu-
lation. The usefulness of the score for individualized diagnostic and
therapeutic decisions needs to be shown.
Supplementary material
Supplementary material is available at Europace online.
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